Psychopharmacology of ADHD in pediatrics: current advances and issues | Zendy

Donald E. Greydanus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Psychopharmacology of ADHD in pediatrics: current advances and issues

Author(s) -

Donald E. Greydanus

Publication year - 2009

Publication title -

neuropsychiatric disease and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.819

H-Index - 67

eISSN - 1178-2021

pISSN - 1176-6328

DOI - 10.2147/ndt.s4075

Subject(s) - methylphenidate , psychopharmacology , medicine , psychiatry , attention deficit hyperactivity disorder , amphetamine , dopamine

Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral developmental disorder found in 3% to 8% of children and adolescents. An important part of ADHD management is psychopharmacology, which includes stimulants, norepinephrine reuptake inhibitors, alpha-2 agonists, and antidepressants. Medications with the best evidence-based support for ADHD management are the stimulants methylphenidate and amphetamine. A number of newer, long-acting stimulants are now available and a number of new medications are considered that are under current research.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research